The end of a shortage of popular weight-loss drugs may mean many people lose access to them
Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...
Investor's Business Daily on MSN4d
Hims & Hers Shares Rallied 22% Over Two Days. Why That Move Is Now At Risk.
Hims stock has rallied almost 22% this week on enthusiasm after the FDA said it will allow compounded versions of Lilly's ...
Seeking Alpha1mon
Lilly asks people who took compounded tirzepatide for their medical records
Eli Lilly (NYSE:LLY) is taking the unusual step of asking people who took compounded versions of their drug tirzepatide, marketed as Zepbound for weight loss and Mounjaro for type 2 diabetes ...
Hosted on MSN4mon
Lilly’s Weight-Loss Drug Is a Huge Hit. Its CEO Wants to Replace It ASAP.
The next step was a larger, expensive clinical study ... The decision to expedite the development of tirzepatide would transform Indianapolis-based Lilly. The drug hit the market in 2022 as ...